Home › Cancer (all types) › NCT02688517

Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer

Targeted Genomic Analysis of Human Cancers

Who can join

Ages 1 and older · All sexes

Inclusion Criteria:

* Karnofsky/Lansky performance score \>= 30
* A signed written informed consent
* Evaluation in surgical/medical/radiation oncology/radiology clinic, with a history of biopsy-confirmed diagnosis of cancer of rare histology and/or poor prognosis with standard therapy; priority will be given to rare cancers with poor prognosis and lack of effective standard therapy; study principal investigator (PI) or designee will review and approve each case before enrollment
* Paraffin blocks of the patient's tumor tissue are available and accessible for analysis

Exclusion Criteria:

* Karnofsky/Lansky performance score \< 30
* Life expectancy \< 3 months

About the study

This research trial studies the use of targeted genomic analysis of blood and tissue samples from patients with cancer. Genomic sequencing is a laboratory method that is used to determine the entire genetic makeup of a specific organism or cell type. Genomic sequencing can be used to find changes in areas of the genome that may be important in the development of cancer. It may also help doctors improve ways to diagnose and treat patients with rare cancers with poor prognosis or lack of effective therapy.

What is being tested

• Cytology Specimen Collection Procedure (other)
• Laboratory Biomarker Analysis (other)

Sponsor: Rutgers, The State University of New Jersey · Participants: 1,100 · Started: 2013-02

Contact the study team

• Clinical Trials Office · Phone: 732-235-2465

Official record on ClinicalTrials.gov — NCT02688517

Locations in the U.S.

Conditions

• Cancer (all types)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.